Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275430 · ClinicalTrials.gov registry record · NA
Assessment of the Precision of the Sherlock 3CG Tip Positioning System
A NA study, sponsored by C. R. Bard.
- Terminated
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01275430 is a NA study that was terminated before completion, run by C. R. Bard. The registered enrollment target is 27 participants.
The verdict
NCT01275430, a NA study, was terminated before completion, sponsored by C. R. Bard.
- TERMINATED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Phase I * determine the location of the peripherally inserted central catheter (PICC) tip upon observation of maximum p-wave amplitude Phase II * determine the precision of PICC placement in the Sherlock 3CG group versus the standard PICC placement
Interventions
- DEVICE Sherlock 3CG
- OTHER Blind Placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275430
The ClinicalTrials.gov registry entry for NCT01275430 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sherlock 3CG is the first listed.
NCT01275430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01275430 about?
NCT01275430 is a clinical study titled "Assessment of the Precision of the Sherlock 3CG Tip Positioning System". Phase I * determine the location of the peripherally inserted central catheter (PICC) tip upon observation of maximum p-wave amplitude Phase II * determine the precision of PICC placement in the Sherlock 3CG group versus the standard PICC placement
What is the current status of trial NCT01275430?
This trial is currently terminated. It is a NA study. The enrollment target is 27 participants. The study started on 2011-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01275430?
The interventions under investigation include: Sherlock 3CG (DEVICE), Blind Placement (OTHER).
Who is sponsoring clinical trial NCT01275430?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.